LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40) , with EC 50 s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1 , is potential for the treatment of type 2 diabetes mellitus (T2DM)
